Anti-IgE Therapy Found Safe and Effective for Chronic Urticaria

Both doses of ligelizumab evaluated met the primary endpoint of superiority to placebo for a complete response at 16 weeks of therapy.
MDedge News

source https://www.medscape.com/viewarticle/980846?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?